In the Journals

Common diabetes medication may increase IBD risk

March 21, 2018
Patients who took dipeptidyl peptidase-4 inhibitors — an increasingly common second-line treatment for type 2 diabetes — showed a 75%…

Oral S1P receptor modulator etrasimod shows benefits in severe UC

March 20, 2018
Arena Pharmaceuticals announced that etrasimod, its novel, oral selective sphingosine 1-phosphate receptor modulator, showed benefits in the…
In the Journals

Artificial sweetener Splenda may worsen IBD symptoms

March 19, 2018
The artificial sweetener Splenda promoted microbial dysbiosis and Crohn’s-like disease in genetically susceptible mice, suggesting that…

Oral anti-TNF meets efficacy endpoints in mild-to-moderate UC trial

March 14, 2018
Protalix BioTherapeutics announced that its novel, oral anti-TNF therapy, OPRX-106, met key efficacy endpoints in a phase 2 trial of patients with…
FDA News

FDA committee supports approval of Xeljanz for UC

March 9, 2018
The FDA Gastrointestinal Drugs Advisory Committee voted yesterday in support of Pfizer’s supplemental new drug application for Xeljanz for…
In the Journals

Bariatric surgery linked to increased risk for IBD

March 7, 2018
Patients with a history of bariatric surgery showed an increased risk for developing new-onset inflammatory bowel disease, according to new research…

Sherman Prize accepting 2018 nominations for IBD leaders

March 6, 2018
Online nominations are now open for the third annual Sherman Prize for Excellence in Crohn’s and Colitis. The prize, awarded by the Bruce and…

CDC: IBD patients are falling short on exercise, sleep

February 28, 2018
Certain health-risk behaviors, psychological distress and chronic conditions are more prevalent among adults with inflammatory bowel disease, which…
Meeting News

IBD patients with uveitis show distinct microbiome signature, suggesting gut-eye axis

February 12, 2018
Patients with inflammatory bowel disease who develop uveitis, a common extra-intestinal manifestation of IBD affecting the eye, showed a unique gut…

Janssen partners with Theravance to develop new IBD drug candidate

February 9, 2018
The Janssen Pharmaceutical Companies of Johnson & Johnson announced a collaboration with Theravance Biopharma to develop a new pan-Janus kinase…